HELP Copays Act
Summary
The HELP Copays Act (HR6423) is an early-stage bill that would ban accumulator adjustment programs, forcing insurers to count manufacturer copay assistance toward patient deductibles. This increases insurer drug cost liability, creating a bearish signal for major health insurers like UnitedHealth, Cigna, and Humana. The bill is in early committee stage with no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HELP Copays Act would ban accumulator adjustment programs, increasing insurer drug cost liability.
- 2.Bearish for commercial health insurers: $UNH, $CI, $HUM.
- 3.Bill is early-stage (referred to committee) with companion bill in Senate; no near-term market impact.
Market Implications
The HELP Copays Act is a regulatory risk for commercial health insurers. If passed, it would increase insurers' drug cost liability by forcing them to count manufacturer copay assistance toward patient deductibles. This directly affects UnitedHealth, Cigna ($CI), and Humana ($HUM), which have large commercial plan membership and currently use accumulator programs. The bill is in early committee stage, so no immediate market reaction is warranted. Investors should monitor committee markups and hearings for signs of momentum. The companion bill S864 having hearings in the Senate HELP Committee is a positive signal for passage probability, but the bill remains early-stage.
Full Analysis
-
On December 4, 2025, Representative Kean (R-NJ) introduced the HELP Copays Act (HR6423) in the House. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It has 52 cosponsors and an identical companion bill (S864) in the Senate, which has had hearings in the HELP Committee. The bill is in early legislative stages and has not been marked up or voted on.
-
The bill does not authorize or appropriate any federal funding. It is a regulatory mandate that would change how health insurers treat manufacturer copay assistance. Currently, many insurers use accumulator adjustment programs that exclude manufacturer copay coupons from counting toward patient deductibles and out-of-pocket maximums. This bill would prohibit that practice, requiring insurers to count all copay assistance toward cost-sharing limits. The mechanism is a statutory prohibition on accumulator programs, enforced through ERISA and PHSA requirements.
-
Structural winners are pharmaceutical companies and patients who benefit from copay assistance programs being more effective. Losers are health insurers who lose the cost-control mechanism of accumulator programs. The primary bearish impact is on commercial health insurers with large employer-group and individual plan membership: UnitedHealth Group, Cigna ($CI), and Humana ($HUM). These insurers currently use accumulator programs to limit their drug cost exposure when manufacturers provide copay coupons for high-cost brand drugs. Banning accumulator programs means insurers cover a larger share of drug costs once patients hit their deductibles faster.
-
No real market data is provided for stock prices. The legislative timeline is early: the bill has been referred to two committees and has a companion bill with hearings in the Senate. The 52 cosponsors indicate some bipartisan support, but the bill has not advanced to markup or floor votes. The 119th Congress (2025-2027) has two years remaining, so the bill could progress but faces significant opposition from the insurance industry.
-
Timeline: The next steps are committee hearings and markups in both the House Energy and Commerce and Ways and Means Committees, and the Senate HELP Committee. If the bill passes both chambers and is signed into law, insurers would need to adjust their plan designs and pricing for the next plan year. Given the early stage and insurance industry opposition, passage is uncertain and likely not imminent.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
The HELP Copays Act would require health insurance plans to count copay assistance from drug manufacturers toward patient deductibles and out-of-pocket maximums, preventing insurers from using accumulator adjustment programs.
Who must act
Health insurance issuers offering group or individual health coverage, including Cigna's employer-sponsored and individual plans.
What happens
Insurers lose the ability to exclude manufacturer copay assistance from patient cost-sharing calculations, increasing their liability for drug costs as patients hit deductibles faster and insurers cover a larger share of drug expenses.
Stock impact
Cigna's health insurance segment, covering ~19 million members, would face higher drug cost exposure on plans where accumulator programs are currently used, potentially increasing medical cost ratios by an estimated 0.5-1.5% for affected commercial plans.
What the bill does
The HELP Copays Act would require health insurance plans to count copay assistance from drug manufacturers toward patient deductibles and out-of-pocket maximums, preventing insurers from using accumulator adjustment programs.
Who must act
Health insurance issuers offering group or individual health coverage, including Humana's employer-sponsored and individual plans.
What happens
Insurers lose the ability to exclude manufacturer copay assistance from patient cost-sharing calculations, increasing their liability for drug costs as patients hit deductibles faster and insurers cover a larger share of drug expenses.
Stock impact
Humana's commercial health insurance segment, covering ~5 million members, would face higher drug cost exposure on plans where accumulator programs are currently used, potentially increasing medical cost ratios by an estimated 0.5-1.5% for affected commercial plans.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Access to Genetic Counselor Services Act of 2025
IDA Act of 2026
Daniel J. Harvey, Jr. and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act
Great American Healthcare Plan
PBM Act
PBM Act
Ensuring Rural Health Care Access for Military and Tribal Families Act
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.